According to Future Market Insights research, during the projected period, the Global point-of-care diagnostics market is expected to grow at a CAGR of 6.8%. The market value is projected to increase from US$ 38.7 Billion in 2023 to US$ 74.8 Billion by 2033. The point-of-care diagnostics market was valued at US$ 36.6 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 5.8% in 2023.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 36.6 Billion |
| Market Value 2023 | US$ 38.7 Billion |
| Market Value 2033 | US$ 74.8 Billion |
| CAGR 2023 to 2033 | 6.8% |
| Share of Top 5 Countries | 56.5% |
| Key Players | The key players in the Global Point-of-Care Diagnostics Market Are F. Hoffmann-La Roche Ltd; Becton Dickinson & Company; Cepheid (Danaher);Siemens Healthineers; Abbott; Diasorin S.p.a.; Thermo Fisher Scientific Inc.; Qiagen; BIOMÉRIEUX; Hologic Inc.; Bio Rad Laboratories; Quidel Corporation; EKF Diagnostics; SEKISUI Diagnostics; DiaSys-Diagnostic Systems GmbH; InBios International; Inc.; Jiangsu Mole Bioscience Co.; Ltd.; ACON Laboratories; Inc.; Visby Medical; Inc.; UNIMA; INC. |
Point-of-Care testing (POCT) refers to medical diagnostic testing that is performed near the patient, usually at the bedside or in a doctor's office, rather than in a central laboratory. The goal of POCT is to provide rapid and accurate diagnostic results that can guide clinical decision-making in real-time.
The world is seeing rapid advancements in a wide range of digital health technologies, including portable and ingestible devices; mobile health apps; artificial intelligence (AI); robots used in healthcare; 3D organ printing; block chain; telemedicine; machine learning; genome research; drones; augmented and virtual reality; and electronic records. However, the market is also shifting to digitalization, so the influx of digital health technologies is a prominent driver for point-of-care diagnostic market.
Accelerating the adoption of proven digital health technologies and advancing their embedding into routine care operations has the potential to revolutionize human health by boosting efficacy, driving costs down, and increasing access to and capacity for care delivery.
New product launches and approvals such as Lab-on-a-chip technology is one of the main drivers of POCT.
Overall, the increasing adoption of latest technologies and new product launches and approvals is likely to boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the global point-of-care diagnostics market grew at a CAGR of 6.2% between 2012 to 2022. Global point-of-care diagnostics market contributes 40.0% revenue share to the global in-vitro diagnostics market valued at US$ 91.2 Billion in 2022.
The increasing prevalence of Infectious diseases has resulted in higher uptake of POC diagnostic options such as Glucose and Hb1Ac testing. Because of their easy availability and rapid diagnosis, point-of-care diagnostics are typically the first form of testing recommended worldwide.
A significant advance has been made in the effort to identify SARS-CoV-2 coronavirus patients with the addition of saliva samples for the purpose of coronavirus identification. Governments concentrated on raising knowledge about COVID-19 testing during the COVID-19 epidemic to ensure an early identification of the illness. As a result of such initiatives, people become more knowledgeable of Point-of-Care testing for the diagnosis of coronavirus.
Creating awareness about diseases is an essential aspect of early detection and screening. If the public has a general understanding of diseases and symptoms, action plans can be better implemented. On the other hand, if there is a lack of awareness, it stops people from taking preventive measures or availing treatments.
Considering this, FMI expects the global market to grow at a CAGR of 6.8% through the forecasted years.
There is a lack of expansion of biotechnology & pharmaceutical Industries regarding point-of-care diagnostics. Biopharmaceuticals are one of modern science's most technically advanced and exquisite achievements. Pharmaceutical companies are putting in a lot of effort to produce medications and lifesaving vaccines and biologicals for the entire world. When the pharmaceutical sector employs biotechnological advancements and advanced processes, the result is better and faster drug delivery. Biotechnology has aided the pharmaceutical sector in the correct manufacturing of vaccines and medications.
The pharmaceutical sector intends to establish products that support the treatment of various diseases. This may result in pharma companies manufacturing point-of-Care (POC) devices.
While greater investment for innovative products is required for the growth of the market, the healthcare infrastructure can have a substantial impact on market expansion. Most healthcare authorities have recently committed increased financing for the development and enhancement of their healthcare infrastructure as a result of the COVID-19 pandemic. The development of Point-of-Care diagnostics kits and their production need more investment.
Overall, healthcare infrastructure for POCT is complex and evolving, and it is important that companies stay abreast of regulatory changes and work closely with regulators to ensure compliance. However, regulatory initiatives that promote safe and effective pain management can create growth opportunities for the POCT market, especially for companies that offer innovative solutions.
Increased testing of point-of-care diagnosis in patients will pave the way for new technology and treatment options, ultimately leading more improvement in healthcare infrastructure and growth in number of manufacturing facilities.
Principal Consultant
Point-of-Care tests in some therapy areas have become more accurate (e.g., glucose testing). Overall, POC tests and rapid tests tend to remain less accurate compared to tests run in a laboratory. Accuracy is essential in medical testing, because an incorrect diagnosis can lead to inappropriate treatment, which can have serious consequences for patients. Inaccurate POC results can lead to false positives or false negatives, which can result in unnecessary treatment or missed diagnosis, respectively.
Inaccurate POCT results can also lead to mistrust in the technology, which can impact the adoption and utilization of POCT products. Healthcare providers may be hesitant to rely on POCT if they have concerns about its accuracy and reliability.
The cost of tests and a lack of trust in POC/ rapid testing are major concerns around the globe. The cost of point-of-care kits or devices is very high as compared to laboratory tests, which is compounded by the lower level of accuracy offered by the former.
Due to financial constraints, academic research laboratories are often unable to purchase expensive equipment. The overall cost of these instruments increases as a result of maintenance costs and other indirect expenses. Thus, the higher cost associated with the equipment and other factors causing unaffordability for the laboratories might hamper the market growth.
These factors are expected to hamper revenue growth of the global market over the forecast period.
USA dominated the global market in 2022 and is further expected to register growth rate at CAGR of 6.8%.
Diagnostic techniques, such as rapid testing or POCT like COVID-19 testing, glucose testing, and allergy tests, etc., has seen a high rate of patient acceptance as a result of the high prevalence. Awareness campaigns and strategic conferences with focus on point-of-care technologies for healthcare sector, has been undertaken by various associations in USA
In May 2022, American Association for Clinical Chemistry, organized a Point-of-Care testing boot camp for POCT professionals and experts in the lab medicine community.
Why is Germany considered to be a Lucrative Market for Point-of-Care Diagnostics?
The general physicians in primary care settings in Germany highly prefer POCTs as a useful diagnostic tool. There are numerous POCTs available in the German market. In the past few years, due to COVID-19 point-of-care diagnostics has been of tremendous importance as first line of defense for testing purpose.
The safe and successful use of point-of-care diagnostics in Germany is likely to influence other European countries to also opt for this method, ultimately resulting in market expansion.
China is projected to be the most attractive market in the east Asia point-of-care diagnostics and is expected to grow over a significant CAGR of 9.0% over the forecast period.
Point-of-care diagnostics market in China is expected to grow significantly in the coming years due to several factors.
One of the main factors driving the growth of the point-of-care diagnostics market in China is the increasing awareness of the condition among the general public and healthcare professionals. As more people become aware of the POC testing, they are more likely to adapt to the testing method, which is leading to increased demand for testing for Point-of-care diagnostics.
Another factor contributing to the growth of the Chinese market is the increasing availability of advanced medical technologies. China has made significant investments in its healthcare infrastructure, and many new hospitals and clinics have been built in recent years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The COVID-19 testing diagnostic segment held the major chunk of about 15.1% in global market by the end of 2022. However, food sensitivity testing is the most lucrative segment over the forecast period due to increase in food allergic cases. Many of allergic reactions require rapid diagnosis that’s where point-of-care diagnostics plays a significant role.
Nasal swabs segment accounted for revenue share of 28.4% in the global market at the end of 2022.
A nasopharyngeal swab, one type of nasal swab, is a test used to look for bacteria or viruses that cause respiratory infections. Your healthcare provider uses a swab to take a small sample of cells from your nasopharynx, the top part of your nose and throat.
Overall, nasal swabs offers a convenient sample type for point-of-care diagnostics for sample withdrawal, making it the largest sample type for this segment.
Handheld POC Monitoring Devices segment accounted for revenue share of 41.3% in the global market at the end of 2022.
Handheld POC monitoring devices can be used to monitor a wide range of medical conditions, such as diabetes, cardiovascular disease, and infectious diseases. For example, a handheld blood glucose meter can be used by patients with diabetes to monitor their blood sugar levels, while a handheld device that measures blood pressure can be used to monitor patients with hypertension.
Overall, Handheld POC Monitoring Devices offers a convenient Product type for Global Point-of-Care diagnostics treating products, making it the largest Product for this segment.
Hospitals held the major chunk of about 27.7% in global market by the end of 2022.
Hospitals offers a convenient end user for POCT market conducting POC tests, making it the dominant end user for this segment. Hospitals segment is set to be highly lucrative in the upcoming years due to ease and access of POCT.
Collaboration are the top strategy being adopted by leading players to expand their product portfolio, their customer base as well as maintain their foothold in the market.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the Point-of-care Diagnostics Market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, and GCC Countries |
| Key Segments Covered | Test Type, Sample, Product, End User, Region |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd; Becton Dickinson & Company; Cepheid (Danaher); Siemens Healthineers; Abbott; Diasorin S.p.a.; Thermo Fisher Scientific Inc.; Qiagen; BIOMÉRIEUX; Hologic Inc.; Bio Rad Laboratories; Quidel Corporation; EKF Diagnostics; SEKISUI Diagnostics; DiaSys-Diagnostic Systems GmbH; InBios International, Inc.; Jiangsu Mole Bioscience Co., Ltd.; ACON Laboratories, Inc.; Visby Medical, Inc.; UNIMA, INC. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The growth potential of the market is 6.8% through 2033.
The United States and Germany are projected to emerge as lucrative markets.
Hospitals offer a convenient end user for the POCT market conducting POC tests, making it the dominant end user.
Handheld POC Monitoring Devices accounted for a revenue share of 41.3% in 2022.
Efforts to produce medications and lifesaving vaccines and biologicals for the entire world drive sales.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends
4. Value-Added Insights
4.1. Disease Epidemiology, By Indication
4.2. Regulatory Scenario
4.3. Reimbursement Landscape
4.4. Unmet Needs and Opportunities
4.5. Point-of-care Testing (POCT) Compared to a Conventional Testing Procedure
4.6. Challenges and Benefits of POCT
4.7. PESTLE Analysis
4.8. Porter’s Analysis
4.9. Value Chain Analysis
4.10. Parent Market Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.1.3. Global In-vitro Diagnostics Market
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Increasing Treatment Seeking Rate
5.2.3. New Test Type Launches/Approvals
5.2.4. Increasing Diagnosis Rate (%) of Infectious Diseases
5.2.5. Increasing Incidence of Chronic Diseases
5.2.6. Rising Adoption of POC Devices
5.2.7. Government Initiatives to Combat Diseases
5.2.8. Companies Increasingly Spending on R&D and Focus on Innovation
5.2.9. Collaborations and Agreements between Manufacturers
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis - Impact Assessment
6.1. COVID-19 and Impact Analysis
6.1.1. By Test Type
6.1.2. By Product
6.1.3. By Sample
6.1.4. By End User
6.1.5. By Country
6.2. 2022 Market Scenario
7. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Volume Analysis, 2012 to 2022
7.2. Current and Future Market Volume Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Assessment
8.1. Global Pricing Analysis
8.2. Pricing Assumptions
9. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012 to 2022 and Forecast, 2023 to 2033
9.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022
9.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Test Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis by Test Type, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Test Type, 2023 to 2033
10.3.1. Infectious Disease
10.3.1.1. HIV POC Testing
10.3.1.2. Clostridium Difficile POC Testing
10.3.1.3. HBV POC Testing
10.3.1.4. Pneumonia or Streptococcus Associated Infections Testing
10.3.1.5. Respiratory Syncytial Virus (RSV) POC Testing
10.3.1.6. HPV POC
10.3.1.7. Influenza/Flu POC Testing
10.3.1.8. HCV POC Testing
10.3.1.9. MRSA POC Testing
10.3.1.10. TB and Drug-resistant TB POC Testing
10.3.1.11. HSV POC Testing
10.3.2. COVID-19 Testing
10.3.3. Glucose Testing
10.3.4. Hb1Ac Testing
10.3.5. Coagulation Testing
10.3.6. Pregnancy & Fertility Testing
10.3.7. Allergy Tests
10.3.8. Cholesterol & Lipids Tests
10.3.9. Drug of Abuse (DOA) Testing
10.3.10. Food Sensitivity Tests
10.3.11. Metabolism Tests
10.3.12. Vitamin D Tests
10.3.13. Vitamins B Test
10.3.14. Urinary Tract Infection (UTI) Tests
10.3.15. Sexual Health Tests
10.3.16. Water Testing Kits
10.3.17. Alcohol Tests
10.3.18. Others
10.4. Market Attractiveness Analysis by Test Type
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis & Volume Analysis by Product, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) & Volume Analysis and Forecast by Product, 2023 to 2033
11.3.1. Dipstick
11.3.2. Strips & Cards
11.3.3. Cassettes
11.3.4. Handheld POC Monitoring Devices
11.4. Market Attractiveness Analysis by Product
12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Sample
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis by Sample, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Sample, 2023 to 2033
12.3.1. Saliva
12.3.2. Nasal Swabs
12.3.3. Urine
12.3.4. Blood
12.3.5. Plasma
12.3.6. Sweat
12.3.7. Other Fluids
12.4. Market Attractiveness Analysis by Product
13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis by End User, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2023 to 2033
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Diagnostic Laboratories
13.3.4. Home Care Settings
13.3.5. Non-Government Organization
13.3.6. Government & Federal Agencies
13.3.7. Long-Term Care Centers
13.4. Market Attractiveness Analysis by End User
14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Region, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Region, 2022-2032
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. South Asia
14.3.5. East Asia
14.3.6. Oceania
14.3.7. Middle East & Africa
14.4. Market Attractiveness Analysis by Country
15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. USA
15.3.1.2. Canada
15.3.2. By Test Type
15.3.3. By Product
15.3.4. By Sample
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Test Type
15.4.3. By Product
15.4.4. By Sample
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants- Intensity Mapping
15.7. Drivers & Restraints Impact Analysis
15.8. Country-wise Analysis
15.8.1. USA Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Test Type
15.8.1.2.2. By Product
15.8.1.2.3. By Sample
15.8.1.2.4. By End User
15.8.2. Canada Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Test Type
15.8.2.2.2. By Product
15.8.2.2.3. By Sample
15.8.2.2.4. By End User
16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Brazil
16.3.1.2. Mexico
16.3.1.3. Argentina
16.3.2. By Test Type
16.3.3. By Product
16.3.4. By Sample
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Test Type
16.4.3. By Product
16.4.4. By Sample
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants- Intensity Mapping
16.7. Drivers & Restraints Impact Analysis
16.8. Country-wise Analysis
16.8.1. Brazil Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Test Type
16.8.1.2.2. By Product
16.8.1.2.3. By Sample
16.8.1.2.4. By End User
16.8.2. Mexico Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Test Type
16.8.2.2.2. By Product
16.8.2.2.3. By Sample
16.8.2.2.4. By End User
16.8.3. Argentina Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Test Type
16.8.3.2.2. By Product
16.8.3.2.3. By Sample
16.8.3.2.4. By End User
17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. UK
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.2. By Test Type
17.3.3. By Product
17.3.4. By Sample
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Test Type
17.4.3. By Product
17.4.4. By Sample
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants- Intensity Mapping
17.7. Drivers & Restraints Impact Analysis
17.8. Country-wise Analysis
17.8.1. Germany Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Test Type
17.8.1.2.2. By Product
17.8.1.2.3. By Sample
17.8.1.2.4. By End User
17.8.2. Italy Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Test Type
17.8.2.2.2. By Product
17.8.2.2.3. By Sample
17.8.2.2.4. By End User
17.8.3. France Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Test Type
17.8.3.2.2. By Product
17.8.3.2.3. By Sample
17.8.3.2.4. By End User
17.8.4. UK Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Test Type
17.8.4.2.2. By Product
17.8.4.2.3. By Sample
17.8.4.2.4. By End User
17.8.5. Spain Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast by Market Taxonomy
17.8.5.2.1. By Test Type
17.8.5.2.2. By Product
17.8.5.2.3. By Sample
17.8.5.2.4. By End User
17.8.6. BENELUX Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast by Market Taxonomy
17.8.6.2.1. By Test Type
17.8.6.2.2. By Product
17.8.6.2.3. By Sample
17.8.6.2.4. By End User
17.8.7. Russia Market Analysis
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast by Market Taxonomy
17.8.7.2.1. By Test Type
17.8.7.2.2. By Product
17.8.7.2.3. By Sample
17.8.7.2.4. By End User
18. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Malaysia
18.3.1.4. Thailand
18.3.1.5. Rest of South Asia
18.3.2. By Test Type
18.3.3. By Product
18.3.4. By Sample
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Test Type
18.4.3. By Product
18.4.4. By Sample
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants- Intensity Mapping
18.7. Drivers & Restraints Impact Analysis
18.8. Country-wise Analysis
18.8.1. India Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Test Type
18.8.1.2.2. By Product
18.8.1.2.3. By Sample
18.8.1.2.4. By End User
18.8.2. Indonesia Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Test Type
18.8.2.2.2. By Product
18.8.2.2.3. By Sample
18.8.2.2.4. By End User
18.8.3. Malaysia Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Test Type
18.8.3.2.2. By Product
18.8.3.2.3. By Sample
18.8.3.2.4. By End User
18.8.4. Thailand Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Test Type
18.8.4.2.2. By Product
18.8.4.2.3. By Sample
18.8.4.2.4. By End User
19. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. China
19.3.1.2. Japan
19.3.1.3. South Korea
19.3.2. By Test Type
19.3.3. By Product
19.3.4. By Sample
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Test Type
19.4.3. By Product
19.4.4. By Sample
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants- Intensity Mapping
19.7. Drivers & Restraints Impact Analysis
19.8. Country-wise Analysis
19.8.1. China Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Test Type
19.8.1.2.2. By Product
19.8.1.2.3. By Sample
19.8.1.2.4. By End User
19.8.2. Japan Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Test Type
19.8.2.2.2. By Product
19.8.2.2.3. By Sample
19.8.2.2.4. By End User
19.8.3. South Korea Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Test Type
19.8.3.2.2. By Product
19.8.3.2.3. By Sample
19.8.3.2.4. By End User
20. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022
20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Test Type
20.3.3. By Product
20.3.4. By Sample
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Test Type
20.4.3. By Product
20.4.4. By Sample
20.4.5. By End User
20.5. Market Trends
20.6. Key Market Participants- Intensity Mapping
20.7. Drivers & Restraints Impact Analysis
20.8. Country-wise Analysis
20.8.1. Australia Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Test Type
20.8.1.2.2. By Product
20.8.1.2.3. By Sample
20.8.1.2.4. By End User
20.8.2. New Zealand Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Test Type
20.8.2.2.2. By Product
20.8.2.2.3. By Sample
20.8.2.2.4. By End User
21. Middle East & Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Market Taxonomy, 2012 to 2022
21.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Country
21.3.1.2. Türkiye
21.3.1.3. South Africa
21.3.1.4. Rest of MEA
21.3.2. By Test Type
21.3.3. By Product
21.3.4. By Sample
21.3.5. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Test Type
21.4.3. By Product
21.4.4. By Sample
21.4.5. By End User
21.5. Market Trends
21.6. Key Market Participants- Intensity Mapping
21.7. Drivers & Restraints Impact Analysis
21.8. Country-wise Analysis
21.8.1. GCC Country Market Analysis
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast by Market Taxonomy
21.8.1.2.1. By Test Type
21.8.1.2.2. By Product
21.8.1.2.3. By Sample
21.8.1.2.4. By End User
21.8.2. Türkiye Market Analysis
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast by Market Taxonomy
21.8.2.2.1. By Test Type
21.8.2.2.2. By Product
21.8.2.2.3. By Sample
21.8.2.2.4. By End User
21.8.3. South Africa Market Analysis
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast by Market Taxonomy
21.8.3.2.1. By Test Type
21.8.3.2.2. By Product
21.8.3.2.3. By Sample
21.8.3.2.4. By End User
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players (%)
22.3. Market Concentration
22.4. Market Presence Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Key Development Analysis
23.3. Branding and Promotional Strategies, By Key Players
23.4. Competition Deep Dive
23.4.1. F. Hoffmann-La Roche Ltd
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Key Financials
23.4.1.4. SWOT Analysis
23.4.1.5. Key Developments
23.4.1.6. Sales Footprint
23.4.1.7. Strategy Overview
23.4.1.7.1. Marketing Strategy
23.4.1.7.2. Product Strategy
23.4.1.7.3. Channel Strategy
23.4.2. Becton Dickinson & Company
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Key Financials
23.4.2.4. SWOT Analysis
23.4.2.5. Key Developments
23.4.2.6. Sales Footprint
23.4.2.7. Strategy Overview
23.4.2.7.1. Marketing Strategy
23.4.2.7.2. Product Strategy
23.4.2.7.3. Channel Strategy
23.4.3. Cepheid (Danaher)
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Key Financials
23.4.3.4. SWOT Analysis
23.4.3.5. Key Developments
23.4.3.6. Sales Footprint
23.4.3.7. Strategy Overview
23.4.3.7.1. Marketing Strategy
23.4.3.7.2. Product Strategy
23.4.3.7.3. Channel Strategy
23.4.4. Siemens Healthineers
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Key Financials
23.4.4.4. SWOT Analysis
23.4.4.5. Key Developments
23.4.4.6. Sales Footprint
23.4.4.7. Strategy Overview
23.4.4.7.1. Marketing Strategy
23.4.4.7.2. Product Strategy
23.4.4.7.3. Channel Strategy
23.4.5. Abbott
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Key Financials
23.4.5.4. SWOT Analysis
23.4.5.5. Key Developments
23.4.5.6. Sales Footprint
23.4.5.7. Strategy Overview
23.4.5.7.1. Marketing Strategy
23.4.5.7.2. Product Strategy
23.4.5.7.3. Channel Strategy
23.4.6. Diasorin S.p.a.
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Key Financials
23.4.6.4. SWOT Analysis
23.4.6.5. Key Developments
23.4.6.6. Sales Footprint
23.4.6.7. Strategy Overview
23.4.6.7.1. Marketing Strategy
23.4.6.7.2. Product Strategy
23.4.6.7.3. Channel Strategy
23.4.7. Thermo Fisher Scientific Inc.
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Key Financials
23.4.7.4. SWOT Analysis
23.4.7.5. Key Developments
23.4.7.6. Sales Footprint
23.4.7.7. Strategy Overview
23.4.7.7.1. Marketing Strategy
23.4.7.7.2. Product Strategy
23.4.7.7.3. Channel Strategy
23.4.8. Qiagen
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Key Financials
23.4.8.4. SWOT Analysis
23.4.8.5. Key Developments
23.4.8.6. Sales Footprint
23.4.8.7. Strategy Overview
23.4.8.7.1. Marketing Strategy
23.4.8.7.2. Product Strategy
23.4.8.7.3. Channel Strategy
23.4.9. BIOMÉRIEUX
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Key Financials
23.4.9.4. SWOT Analysis
23.4.9.5. Key Developments
23.4.9.6. Sales Footprint
23.4.9.7. Strategy Overview
23.4.9.7.1. Marketing Strategy
23.4.9.7.2. Product Strategy
23.4.9.7.3. Channel Strategy
23.4.10. Hologic Inc.
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Key Financials
23.4.10.4. SWOT Analysis
23.4.10.5. Key Developments
23.4.10.6. Sales Footprint
23.4.10.7. Strategy Overview
23.4.10.7.1. Marketing Strategy
23.4.10.7.2. Product Strategy
23.4.10.7.3. Channel Strategy
23.4.11. Bio Rad Laboratories
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Key Financials
23.4.11.4. SWOT Analysis
23.4.11.5. Key Developments
23.4.11.6. Sales Footprint
23.4.11.7. Strategy Overview
23.4.11.7.1. Marketing Strategy
23.4.11.7.2. Product Strategy
23.4.11.7.3. Channel Strategy
23.4.12. Quidel Corporation
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Key Financials
23.4.12.4. SWOT Analysis
23.4.12.5. Key Developments
23.4.12.6. Sales Footprint
23.4.12.7. Strategy Overview
23.4.12.7.1. Marketing Strategy
23.4.12.7.2. Product Strategy
23.4.12.7.3. Channel Strategy
23.4.13. EKF Diagnostics
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Key Financials
23.4.13.4. SWOT Analysis
23.4.13.5. Key Developments
23.4.13.6. Sales Footprint
23.4.13.7. Strategy Overview
23.4.13.7.1. Marketing Strategy
23.4.13.7.2. Product Strategy
23.4.13.7.3. Channel Strategy
23.4.14. SEKISUI Diagnostics
23.4.14.1. Overview
23.4.14.2. Product Portfolio
23.4.14.3. Key Financials
23.4.14.4. SWOT Analysis
23.4.14.5. Key Developments
23.4.14.6. Sales Footprint
23.4.14.7. Strategy Overview
23.4.14.7.1. Marketing Strategy
23.4.14.7.2. Product Strategy
23.4.14.7.3. Channel Strategy
23.4.15. DiaSys-Diagnostic Systems GmbH
23.4.15.1. Overview
23.4.15.2. Product Portfolio
23.4.15.3. Key Financials
23.4.15.4. SWOT Analysis
23.4.15.5. Key Developments
23.4.15.6. Sales Footprint
23.4.15.7. Strategy Overview
23.4.15.7.1. Marketing Strategy
23.4.15.7.2. Product Strategy
23.4.15.7.3. Channel Strategy
23.4.16. InBios International, Inc.
23.4.16.1. Overview
23.4.16.2. Product Portfolio
23.4.16.3. Key Financials
23.4.16.4. SWOT Analysis
23.4.16.5. Key Developments
23.4.16.6. Sales Footprint
23.4.16.7. Strategy Overview
23.4.16.7.1. Marketing Strategy
23.4.16.7.2. Product Strategy
23.4.16.7.3. Channel Strategy
23.4.17. Jiangsu Mole Bioscience Co., Ltd.
23.4.17.1. Overview
23.4.17.2. Product Portfolio
23.4.17.3. Key Financials
23.4.17.4. SWOT Analysis
23.4.17.5. Key Developments
23.4.17.6. Sales Footprint
23.4.17.7. Strategy Overview
23.4.17.7.1. Marketing Strategy
23.4.17.7.2. Product Strategy
23.4.17.7.3. Channel Strategy
23.4.18. ACON Laboratories, Inc.
23.4.18.1. Overview
23.4.18.2. Product Portfolio
23.4.18.3. Key Financials
23.4.18.4. SWOT Analysis
23.4.18.5. Key Developments
23.4.18.6. Sales Footprint
23.4.18.7. Strategy Overview
23.4.18.7.1. Marketing Strategy
23.4.18.7.2. Product Strategy
23.4.18.7.3. Channel Strategy
23.4.19. Visby Medical, Inc.
23.4.19.1. Overview
23.4.19.2. Product Portfolio
23.4.19.3. Key Financials
23.4.19.4. SWOT Analysis
23.4.19.5. Key Developments
23.4.19.6. Sales Footprint
23.4.19.7. Strategy Overview
23.4.19.7.1. Marketing Strategy
23.4.19.7.2. Product Strategy
23.4.19.7.3. Channel Strategy
23.4.20. UNIMA, INC.
23.4.20.1. Overview
23.4.20.2. Product Portfolio
23.4.20.3. Key Financials
23.4.20.4. SWOT Analysis
23.4.20.5. Key Developments
23.4.20.6. Sales Footprint
23.4.20.7. Strategy Overview
23.4.20.7.1. Marketing Strategy
23.4.20.7.2. Product Strategy
23.4.20.7.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Point-of-Care Diagnostics Market
